References
- Sandler SG, Flegel WA, Westhoff CM, et al. It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype. Transfusion 2015;55:680–9.
- AABB. Joint statement on phasing-in RHD genotyping for pregnant women and other females of childbearing potential with a serologic weak D phenotype. Available from http://www.aabb.org/advocacy/statements/Pages/statement150722.aspx (February 9, 2017).
- Keller MA, Crowley J, Horn T, et al. Characterization of RH locus in African American blood donors. Transfusion 2013; 53(2 Suppl):28A.
- Queenan JT. Rh immunoprophylaxis and fetal RHD Genotyping: where are we going? Obstet Gynecol 2012;120: 219–20.
- Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012;120:1132–9.
- Hartwell EA. Use of Rh immune globulin: ASCP practice parameter. Am J Clin Pathol. 1998;110:281–92.
- Reid M, Lomas-Francis C, Olsson M. The blood group antigen factsbook. 3rd ed. London: Academic Press; 2012:147–262.
- Denomme GA, Wagner FF, Fernandes BJ, Li W, Flegel WA. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005;45:1554–60.
- Flegel WA, Denomme GA, Yazer MH. On the complexity of D antigen typing: a handy decision tree in the age of molecular blood group diagnostics. J Obstet Gynaecol Can. 2007;29:746–52.
- Keller MA. The role of red cell genotyping in transfusion medicine. Immunohematology 2015;31:49–52.
- Luo X, Keller MA, James I, et al. Strategies to identify candidates for D variant genotyping. Blood Transfus 2018;16:293–301.
- Hawk AF, Chang EY, Shields SM, Simpson KN. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol 2013;122:579–85.
- Clausen FB, Rieneck K, Krog GR, Bundgaard BS, Dziegiel MH. Noninvasive antenatal screening for fetal RHD in RhD negative women to guide targeted anti-D prophylaxis. Methods Mol Biol. 2019;1885:347–59.
- Chen Q, Flegel WA. Random survey for RHD alleles among D+ European persons. Transfusion 2005;45:1183–91.
- Flegel WA. Blood group genotyping in Germany. Transfusion 2007;47(1 Suppl):47S–53S.
- Pham BN, Roussel M, Peyrard T, et al. Anti-D investigations in individuals expressing weak D type 1 or weak D type 2: allo- or autoantibodies? Transfusion 2011;51:2679–85.
- Hemker MB, Ligthart PC, Berger L, van Rhenen DJ, van der Schoot CE, Wijk PA. DAR, a new RhD variant involving exons 4, 5, and 7, often in linkage with ceAR, a new Rhce variant frequently found in African blacks. Blood 1999;94:4337–42.
- Horn T, Crowley JA, Keller MA. RhD typing discrepancies resolved through RHD genotyping: a patient perspective. Transfusion 2014;54:29A.
- Sandler SG, Roseff SD, Domen RE, Shaz B, Gottschall JL. Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the Comprehensive Transfusion Medicine survey of the College of American Pathologists. Arch Pathol Lab Med 2014;138:620–5.
- Kacker S, Vassallo R, Keller MA, et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion 2015;55:2095–103
- ISBT. Red cell immunogenetics and blood group terminology. Available from: http://www.isbtweb.org/working-parties/ red-cell-immunogenetics-and-blood-group-terminology/. Accessed 24 December 2020.
- The Human RhesusBase, version 2.5, http://www.rhesusbase.info/, update 2020-03-18. Accessed 24 December 2020.
- Westhoff C, Nance S, Lomas-Francis C, Keller MA, Chou S. Experience with RHD*weak D type 4.0 in the USA. Blood Transfus 2019;17:91–3.
- Wagner FF, Eicher NI, Jørgensen JR, Lonicer CB, Flegel WA. DNB: a partial D with anti-D frequent in Central Europe. Blood 2002;100:2253–6.
- Flegel WA, Denomme GA, Queenan JT, et al. It’s time to phase out “serologic weak D phenotype” and resolve D types with RHD genotyping including weak D type 4. Transfusion 2020;60:855–9.